MedPath

Chiauranib

Generic Name
Chiauranib
Brand Names
-
Drug Type
Small Molecule
Chemical Formula
C27H21N3O3
CAS Number
1256349-48-0
Unique Ingredient Identifier
F40IRN5981
Background

Chiauranib is under investigation in clinical trial NCT03974243 (Chiauranib in Combination With Chidamide in Patients With Relapsed/refractory Non-hodgkin's Lymphoma).

Indication

用于治疗经过2线系统化疗方案后疾病进展或复发的小细胞肺癌（SCLC）。

Associated Conditions
-
Associated Therapies
-
Clinical Trials
Related News

Study of Chiauranib in Patients With Advanced Hepatocellular Carcinoma

Phase 1
Completed
Conditions
Hepatocellular Carcinoma
Interventions
Drug: Chiauranib
First Posted Date
2017-08-10
Last Posted Date
2021-06-18
Lead Sponsor
Chipscreen Biosciences, Ltd.
Target Recruit Count
27
Registration Number
NCT03245190
Locations
🇨🇳

Zhongshan Hospital of Fudan University, Shanghai, Shanghai, China

Phase Ib/II Study of Chiauranib in Patients With Small Cell Lung Cancer

Phase 1
Completed
Conditions
Small Cell Lung Cancer
Interventions
Drug: Chiauranib
First Posted Date
2017-07-13
Last Posted Date
2023-08-30
Lead Sponsor
Chipscreen Biosciences, Ltd.
Target Recruit Count
48
Registration Number
NCT03216343
Locations
🇨🇳

Beijing Cancer Hospital, Beijing, Beijing, China

Phase Ib Study of Chiauranib in Patients With Ovarian Cancer

Phase 1
Completed
Conditions
Ovarian Cancer
Interventions
Drug: Chiauranib
First Posted Date
2017-05-25
Last Posted Date
2020-01-18
Lead Sponsor
Chipscreen Biosciences, Ltd.
Target Recruit Count
25
Registration Number
NCT03166891
Locations
🇨🇳

Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

Study of Chiauranib in Relapsed/Refractory Non-Hodgkin's Lymphoma

Phase 1
Terminated
Conditions
Non-Hodgkin's Lymphoma
Interventions
Drug: Chiauranib
First Posted Date
2017-03-09
Last Posted Date
2019-07-24
Lead Sponsor
Chipscreen Biosciences, Ltd.
Target Recruit Count
5
Registration Number
NCT03074825
Locations
🇨🇳

Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China

Phase I Study of Chiauranib in Patients With Advanced Solid Tumors

Phase 1
Completed
Conditions
Solid Tumors
Interventions
Drug: Chiauranib
First Posted Date
2014-04-25
Last Posted Date
2016-06-17
Lead Sponsor
Chipscreen Biosciences, Ltd.
Target Recruit Count
18
Registration Number
NCT02122809
Locations
🇨🇳

Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy